Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4Withdrawn 2Terminated 2Unknown 1Recruiting 1

Sponsor Class

NIH 21INDUSTRY 5OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1NET 1Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × OTHER × MK 2206 × Clear all
NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
334 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01370070 2017-01-13

MC1079

Chinese University of Hong Kong

Phase 2 Completed
12 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT01169649 2016-02-18

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
11 enrolled 6 charts
EndocrineNET

Neuroendocrine Tumors

NCT01235897 2014-04-17

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

University of California, San Francisco

Phase 1 Completed
17 enrolled 7 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡